Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.47 USD
Change Today 0.00 / 0.00%
Volume 0.0
PRGB On Other Exchanges
Symbol
Exchange
OTC BB
As of 8:10 PM 07/29/15 All times are local (Market data is delayed by at least 15 minutes).

protea biosciences group inc (PRGB) Snapshot

Open
$0.47
Previous Close
$0.47
Day High
$0.47
Day Low
$0.47
52 Week High
08/15/14 - $0.80
52 Week Low
06/24/15 - $0.10
Market Cap
51.3M
Average Volume 10 Days
3.3K
EPS TTM
$-0.16
Shares Outstanding
109.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PROTEA BIOSCIENCES GROUP INC (PRGB)

Related News

No related news articles were found.

protea biosciences group inc (PRGB) Related Businessweek News

No Related Businessweek News Found

protea biosciences group inc (PRGB) Details

Protea Biosciences Group, Inc., molecular information company, develops and commercializes proprietary life science technologies, products, and services to identify the molecules that are produced by living cells and various life forms. The company provides molecular information services for the identification of small and large molecules; and tissue analytics services to create tissue-based molecular profiles. It also offers laser ablation electrospray ionization, a bioanalytical instrument platform that enables the identification of proteins, lipids, and metabolites in tissue, cells, and biofluids, such as serum and urine with minimal or without any sample preparation prior to analysis. It primarily serves pharmaceutical and academic/clinical research laboratories; and pharmaceutical, biotechnology, chemical, and medical device companies through field sales, distributors, in-house sales support, and Web-based marketing. The company was founded in 2001 and is based in Morgantown, West Virginia.

39 Employees
Last Reported Date: 05/1/15
Founded in 2001

protea biosciences group inc (PRGB) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $240.0K
Chief Financial Officer
Total Annual Compensation: $145.6K
Vice President of Operations
Total Annual Compensation: $210.0K
Chief Science Officer and Vice President of R...
Total Annual Compensation: $153.9K
Vice President of Corporate Finance and Devel...
Total Annual Compensation: $131.0K
Compensation as of Fiscal Year 2014.

protea biosciences group inc (PRGB) Key Developments

Protea Biosciences Group, Inc. Announces New Silicon Chip Technology

Protea Biosciences Group Inc. announced new, silicon chip technology that enables the rapid identification and quantitation of small molecules in biofluids. The announcement was made at the 63rd American Society of Mass Spectrometry (ASMS) Conference on Mass Spectrometry and Allied Topics, held in St. Louis, MO. Known as REDIchip ("Resonance-Enhanced Desorption Ionization"), the product employs a patented, "nanopost array" (NAPA) nanotechnology invented in the laboratory of Prof. Akos Vertes, PhD., Department of Chemistry, The George Washington University, and exclusively licensed to Protea. REDIchip technology was developed by Protea in conjunction with a $14 million DARPA cooperative research agreement led by The George Washington University and including GE Global Research and SRI International. The project goal is to develop new tools to elucidate the mechanism of action of a threat agent, drug, biologic or chemical on living cells within 30 days from exposure. Uncovering the mechanism of action of such agents in 30 days compared to the years currently required will enhance and support the development of effective threat mitigations and countermeasures. REDIchip is formatted as a disposable, single use, 96 spot, target plate, suitable for simple and complex biological mixtures, and compatible with most standard MALDI-MS instrument systems.

Protea Biosciences Group, Inc Announces Board Appointments

Effective April 17, 2015, Maged Shenouda and Patrick Gallagher were appointed by the board of directors of Protea Biosciences Group Inc. to serve as directors to fill existing vacancies on the Board. Maged Shenouda has over 25 years of experience in the pharmaceutical and securities industries. Most recently, Mr. Shenouda was the Head of Business Development and Licensing at Retrophin Inc. Patrick Gallagher, CFA, is an accomplished Capital Markets executive, advisor and investor with a distinguished record of success in both the public and private markets with a focus on healthcare, agriculture and industrials. He is a Managing Director and Head of Institutional Sales for Laidlaw & Company (UK) Ltd. Mr. Gallagher sits on the board of directors for BioSig Technologies Inc.

Protea Biosciences Group, Inc Presents at SeeThruEquity 4th Annual MicroCap Investor Conference, May-28-2015 03:30 PM

Protea Biosciences Group, Inc Presents at SeeThruEquity 4th Annual MicroCap Investor Conference, May-28-2015 03:30 PM. Venue: Convene Grand Central, 101 Park Ave, New York, NY 10178, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PRGB:US $0.47 USD 0.00

PRGB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PRGB.
View Industry Companies
 

Industry Analysis

PRGB

Industry Average

Valuation PRGB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 27.6x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 27.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PROTEA BIOSCIENCES GROUP INC, please visit www.proteabio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.